Abstract
This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinupristin-dalfopristin against seven hetero-VISA strains and two methicillin-resistant S. aureus strains were evaluated by the time-kill assay. The combinations of arbekacin with vancomycin, teicoplanin, or ampicillin-sulbactam showed the synergistic interaction against hetero-VISA strains. Data suggest that these arbekacin-based combination regimens may be useful candidates for treatment options of hetero-VISA infections.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminoglycosides / administration & dosage*
-
Ampicillin / administration & dosage
-
Anti-Bacterial Agents / administration & dosage*
-
Dibekacin / administration & dosage
-
Dibekacin / analogs & derivatives*
-
Drug Resistance, Bacterial
-
Drug Synergism
-
Humans
-
In Vitro Techniques
-
Methicillin Resistance
-
Microbial Sensitivity Tests
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / isolation & purification
-
Sulbactam / administration & dosage
-
Teicoplanin / administration & dosage
-
Vancomycin / administration & dosage*
-
Virginiamycin / administration & dosage
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Virginiamycin
-
quinupristin-dalfopristin
-
Dibekacin
-
Teicoplanin
-
sultamicillin
-
Vancomycin
-
Ampicillin
-
arbekacin
-
Sulbactam